Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13951
|
Title: | Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B |
Authors: | Hu, HH;Jeng, WJ;Pan, MH;Luo, WS;Chang, CL;Huang, YT;Su, CY;Chiang, CT;Jen, CL;Chien, YC;Lu, SN;Wang, LY;Huang, LR;Lee, MH;Liu, J;Nguyen, MH;Chen, CJ;Yang, HI |
Contributors: | Institute of Molecular and Genomic Medicine |
Abstract: | Background Hepatitis B surface antigen (HBsAg) seroclearance is the most important milestone indicating favourable clinical outcomes in patients with chronic hepatitis B (CHB). However, it is difficult to achieve due to the impaired HBV-specific immunity, such as programmed cell death 1 (PD-1)-associated T cell exhaustion. We assessed soluble PD-1 (sPD-1) as a novel seromarker for predicting spontaneous HBsAg loss. Methods Serial serum levels of sPD-1 were evaluated in 1046 untreated hepatitis B e antigen (HBeAg)-seronegative individuals who had achieved undetectable serum HBV DNA. Multiple regression analyses were applied to assess associations among baseline and subsequent sPD-1 levels, HBsAg decline during follow-up, and spontaneous HBsAg seroclearance. Results A total of 390 individuals achieved spontaneous HBsAg seroclearance during 6464.4 person-years of follow-up. Baseline sPD-1 levels were inversely associated with baseline HBsAg levels (qHBsAg) as well as a greater decline in qHBsAg during follow-up. Incidence rates of HBsAg seroclearance were 11.5, 61.7, 96.7 and 151.0 per 1000 person-years for sPD-1 levels of >= 4000, 536-3999, 125-535 and <125 pg/mL, respectively (P-trend < 0.0001). Compared with baseline sPD-1 levels >= 4000 pg/mL, the rate ratio (95% CI) of HBsAg seroclearance was 2.1 (1.1-3.9), 3.0 (1.6-5.5) and 5.1 (2.8-9.5), for baseline sPD-1 levels of 536-3999, 125-535 and <125 pg/mL, respectively, after adjustment for sex, age and serum alanine aminotransferase and HBsAg levels. Conclusion sPD-1 level is a novel marker which independently predicts spontaneous HBsAg seroclearance of HBeAg-negative inactive CHB patients with undetectable HBV DNA. (word count: 234, <250). |
Date: | 2022-03 |
Relation: | Alimentary Pharmacology and Therapeutics. 2022 Mar;55(5):558-567. |
Link to: | http://dx.doi.org/10.1111/apt.16752 |
JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0269-2813&DestApp=IC2JCR |
Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000742528000001 |
Appears in Collections: | [黃麗蓉] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
ISI000742528000001.pdf | | 830Kb | Adobe PDF | 189 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|